Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers
- PMID: 1535302
- DOI: 10.1038/clpt.1992.85
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers
Abstract
In previous studies serotonin uptake inhibitors such as citalopram decreased alcohol consumption in alcoholics. The mechanism of the effect is not fully understood. This study tested the hypothesis that it is mediated by changes in desire to drink and alcohol effects. After a 1-week baseline period, subjects (13 men and three women; aged 26 to 69 years; healthy, nondepressed, alcohol-dependent drinkers [mean, 6.6 drinks per day]) were randomized in a double-blind fashion to receive 40 mg/day citalopram and placebo for 1 week each, separated by a 1-week washout period. Daily standard alcoholic drinks (13.6 gm ethanol), nonalcoholic drinks, and tobacco use were recorded; evening urine samples were taken; and interest, desire, craving, and liking for alcohol were rated. Medical status, depression, and anxiety were assessed weekly, but no other treatment or advice was given. Daily alcoholic drinks significantly decreased during citalopram treatment (mean +/- SEM = 4.6 +/- 0.6) compared with placebo (5.7 +/- 0.8; p = 0.01), and the average decrease was 17.5%. Percentage of days abstinent increased during citalopram administration (27.7% +/- 5.7%) compared with placebo (15.5% +/- 3.7%; p less than 0.01). Citalopram decreased interest, desire, craving, and liking for alcohol (all p less than 0.05). There was clear internal validation of these measures in that variations in each correlated with alcohol consumption (all r greater than 0.5, p less than 0.05). Nonalcoholic drinks, self-reports of cigarettes smoked (daily smokers), and body weight did not change significantly. In experimental bar sessions, after the citalopram and placebo periods, subjects were required to consume as many of 18 minidrinks as possible (equivalent to six standard drinks) at 5-minute intervals. Subjects rated their desire for alcohol, intoxication, and mood. Citalopram had no significant effects on the desirability of alcohol or subjective feelings of intoxication. The findings indicate that serotonin uptake inhibitors may act by decreasing the urge to drink and the reinforcing effects of alcohol. Also, a naturalistic outpatient trial is a sensitive, simple, and economic procedure for detecting these drug effects.
Similar articles
-
Fluoxetine attenuates alcohol intake and desire to drink.Int Clin Psychopharmacol. 1994 Sep;9(3):163-72. doi: 10.1097/00004850-199409000-00004. Int Clin Psychopharmacol. 1994. PMID: 7814825 Clinical Trial.
-
Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects.Addiction. 1995 Jul;90(7):893-905. doi: 10.1046/j.1360-0443.1995.9078933.x. Addiction. 1995. PMID: 7663312 Clinical Trial.
-
Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.Alcohol Alcohol Suppl. 1993;2:221-9. Alcohol Alcohol Suppl. 1993. PMID: 7748304 Review.
-
Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.Addiction. 1995 Jan;90(1):87-99. doi: 10.1046/j.1360-0443.1995.9018712.x. Addiction. 1995. PMID: 7888983 Clinical Trial.
-
Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications.EXS. 1994;71:209-19. doi: 10.1007/978-3-0348-7330-7_21. EXS. 1994. PMID: 8032152 Review.
Cited by
-
Citalopram--a review of pharmacological and clinical effects.J Psychiatry Neurosci. 2000 May;25(3):241-54. J Psychiatry Neurosci. 2000. PMID: 10863884 Free PMC article. Review.
-
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.Clin Pharmacokinet. 1997 Nov;33(5):344-400. doi: 10.2165/00003088-199733050-00003. Clin Pharmacokinet. 1997. PMID: 9391747 Review.
-
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Biochem Pharmacol. 2008 Jan 1;75(1):34-56. doi: 10.1016/j.bcp.2007.08.005. Epub 2007 Aug 9. Biochem Pharmacol. 2008. PMID: 17880925 Free PMC article. Review.
-
Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction.Neurotox Res. 2002 Jun;4(4):343-61. doi: 10.1080/10298420290034231. Neurotox Res. 2002. PMID: 12829424
-
Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014. Subst Abuse Rehabil. 2014. PMID: 24648792 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical